Last $224.45 USD
Change Today +7.81 / 3.61%
Volume 1.1M
ICPT On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 10/17/14 All times are local (Market data is delayed by at least 15 minutes).

intercept pharmaceuticals in (ICPT) Snapshot

Open
$222.71
Previous Close
$216.64
Day High
$237.49
Day Low
$216.75
52 Week High
01/10/14 - $497.00
52 Week Low
11/8/13 - $46.81
Market Cap
4.8B
Average Volume 10 Days
655.9K
EPS TTM
$-16.56
Shares Outstanding
21.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTERCEPT PHARMACEUTICALS IN (ICPT)

intercept pharmaceuticals in (ICPT) Related Businessweek News

No Related Businessweek News Found

intercept pharmaceuticals in (ICPT) Details

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase II clinical trial for the treatment of alcoholic hepatitis; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea. The company was founded in 2002 and is headquartered in New York, New York.

50 Employees
Last Reported Date: 03/14/14
Founded in 2002

intercept pharmaceuticals in (ICPT) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $934.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $556.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $626.5K
Compensation as of Fiscal Year 2013.

intercept pharmaceuticals in (ICPT) Key Developments

Intercept Announces Data to be Presented at 2014 AASLD Annual Meeting

Intercept Pharmaceuticals, Inc. announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (the Liver Meeting(R)), being held in Boston, Massachusetts from November 7-11, 2014. Obeticholic acid (OCA), Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR) in development for primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and other chronic liver and intestinal diseases. Intercept is also developing the preclinical product candidates INT-777 (an agonist of TGR5, a bile acid receptor) and INT-767 (a dual FXR/TGR5 agonist).

Intercept Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 04:40 PM

Intercept Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 04:40 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Mark Pruzanski, Founder, Chief Executive Officer, President and Director.

Intercept Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-18-2014 09:45 AM

Intercept Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-18-2014 09:45 AM. Venue: Bank of America Merrill Lynch Financial Centre, London, United Kingdom. Speakers: Mark Pruzanski, Founder, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICPT:US $224.45 USD +7.81

ICPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ICPT.
View Industry Companies
 

Industry Analysis

ICPT

Industry Average

Valuation ICPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2,733.4x
Price/Book 15.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2,586.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERCEPT PHARMACEUTICALS IN, please visit www.interceptpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.